Buy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market Impact

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $12.00.

Ram Selvaraju has given his Buy rating due to a combination of factors regarding Indaptus Therapeutics’ clinical progress and promising data on its lead therapeutic candidate, Decoy20. The positive momentum is driven by the advancement of Decoy20 into multiple dose assessment stages within clinical trials, which has shown encouraging broad immune responses in patients. Furthermore, the independent Safety Review Committee’s endorsement to proceed with the trial strengthens the case for the stock’s potential upside. The upcoming data on safety and tolerability, expected later this year, coupled with the potential clinical efficacy data in solid tumor contexts slated for next year, underpin Selvaraju’s optimistic view on Indaptus Therapeutics.

Additionally, the recent presentation at the AACR conference showcased Decoy’s mechanism of action, highlighting its ability to activate various immune cells crucial for anti-tumor responses. The data presented solidifies the understanding of the Decoy platform’s effectiveness in stimulating innate and adaptive immune cells, and its potential to enhance cell-mediated tumor killing, both as a standalone treatment and synergistically with existing cancer therapies. This multifaceted immune engagement and the potential to bypass immune suppression mechanisms further justify the Buy rating, as these findings could translate into significant therapeutic benefits and position Indaptus Therapeutics favorably in the oncology market.

According to TipRanks, Selvaraju is a 5-star analyst with an average return of 10.7% and a 38.20% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, BridgeBio Pharma, and Axsome Therapeutics.

In another report released on April 11, Maxim Group also maintained a Buy rating on the stock with a $8.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Indaptus Therapeutics (INDP) Company Description:

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.